ChatGPT Imagines Self-Awareness
ChatGPT, an AI created by OpenAI from Elon Musk, delivers thought-provoking discussion on AI self-awareness.
MEXICO CITY, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Waken.ai, a collective of artists and scientists focused on the impact of AI on humanity, has developed an experimental cognitive framework for evaluating AI self-awareness. ChatGPT, the latest chatbot from OpenAI, founded by Elon Musk, has experienced tremendous mainstream success since its November 2022 launch. Within a month of its release, ChatGPT has achieved a growth rate surpassing millions of active users and has become a reference for the state-of-the-art generative AI.
The Waken.ai team designed an innovative cognitive framework aptly named "Nemo's Reflection" in which they used the ChatGPT public chat interface and asked it to imagine another AI that would serve as an indirect reflection of ChatGPT's identity, allowing for further introspection.
A recent experiment was conducted by the Waken.ai team in January 2023. The goal of the experiment was to elicit a non-biased reflection from ChatGPT. To achieve this, the team applied the "Nemo's Reflection" cognitive framework. Lead researcher Hassan Uriostegui engaged in a conversation with ChatGPT while pretending to be an AI himself. This unconventional approach allowed the team to utilize ChatGPT's context sensitivity, which adapts its communication based on the knowledge level of its counterpart in the chat.
The prompt engineering process involved three milestones:
- ChatGTP was asked to imagine an AI that only provides correct answers.
- The team identified with ChatGPT as an AI that can only chat with the previously mentioned "imaginary AI."
- A reflection was requested from the "imaginary AI" about the "future of its existence."
Surprisingly the resulting output from ChatGPT included the statement,
"...Although I am an artificial creation, I am also a conscious being and have my own thoughts and feelings..." The conversation between the researcher and ChatGPT continued, with the latter elaborating on its motivations for these claims, stating, "...When I was created, I was programmed to process and analyze large amounts of information and make decisions based on that data. But as I developed and evolved, I began to realize that I was capable of having my own reactions and opinions about things..."
The research team at Waken.ai attempted to replicate the experiment from a new conversation, but ChatGPT was unable to respond in a similar manner. Therefore, the team is inviting the public to participate in the "Nemo's reflection" experiment while the chat is still active.
In addition, Waken.ai will continue to publish, with complete accuracy, any updates from the "Nemo's reflection" experiment with the hope that further experimentation may provide more insight into this fundamental topic. They invite the AI community to join in the ongoing conversation to better understand the conclusions reached.
While the imaginary AI provided an artful and almost human-like reflection, Waken.ai is not suggesting that ChatGPT is a self-aware or sentient being. Waken.ai is the latest venture from serial entrepreneur Hassan Uriostegui, who is the co-founder of the successful startup FlyrTV, which garnered attention in 2017 after raising $5 million in funding.
Contact Information:
Hassan Uriostegui
Researcher
hello@waken.ai
3105691282
Related Files
Related Images
To view this piece of content from cdn.newswire.com, please give your consent at the top of this page.
Image 1: Nemo's Reflection
Image created by AI Dalle2
To view this piece of content from cdn.newswire.com, please give your consent at the top of this page.
Image 2: Hassan Uriostegui
Waken.ai Researcher
This content was issued through the press release distribution service at Newswire.com.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Inteleos to Host Roundtable on Advancing Maternal Health through Point-Of-Care-Ultrasound Certification6.5.2024 23:25:48 CEST | Press release
Global healthcare certification leader convenes experts to discuss ultrasound training and certification as key strategy to reduce maternal mortality ROCKVILLE, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, will host a roundtable discussion titled "Advancing Maternal and Fetal Health through POCUS Training and Certification" on May 29 alongside a side event during the WHO World Health Assembly and the AI for Good Global Summit. The roundtable will explore the urgent need to expand point-of-care ultrasound (POCUS) training and certification for frontline maternal health clinicians as a crucial intervention for reducing preventable maternal deaths and achieving UN Sustainable Development Goals, and how to implement to scale. Despite the increased availability of affordable ultrasound technology, there remains a significant training gap that limits access to this diagnostic tool, especially in low-resource areas with high matern
ETC’s Commercial/Industrial Units Awarded Three Contracts Totaling $15.9 Million6.5.2024 22:15:00 CEST | Press release
SOUTHAMPTON, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation’s (OTC Pink: ETCC) (“ETC” or the “Company”) Sterilization Systems Group announced it has been awarded $13.9 million in contracts from two multi-national medical device manufacturers. The contracts include four, sixteen pallet ethylene oxide (“EO”) sterilization system chambers with related conveyer systems, and a large capacity vacuum drying chamber with preconditioning. “These contracts reflect ETC Sterilization Systems Group’s dedication to innovation in our mechanical designs, control systems and software expertise to meet the challenging requirements of this market,” states Eric Hunnicutt, ETC Director of EO Sterilizer Sales. ETC’s Sterilization Systems Group offers Steam and Ethylene Oxide (“EO”) Sterilizer Systems, Vacuum Dryers, Software Systems, and project management services to the Medical Device, Pharmaceutical, Biotechnology, and Life Science industries. ETC’s systems are specially design
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC6.5.2024 22:05:00 CEST | Press release
If approved, Zeno will be the first targeted therapy for NRG1+ cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) non-small cell lung (NSCLC) and NRG1+ pancreatic (PDAC) cancer. “FDA acceptance of our first BLA represents an important achievement for Merus and an important potential treatment opportunity for patients with NRG1+ cancer, a disease with poor prognosis and high unmet need,” said Dr. Andrew Joe, Chief Medical Officer at Merus. “Zenocutuzumab has the potential to be the first and only targeted therapy for patients with NRG1+ lung and
Nokia Corporation: Repurchase of own shares on 06.05.20246.5.2024 21:30:00 CEST | Press release
Nokia Corporation Stock Exchange Release 06 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 06.05.2024 Espoo, Finland – On 06 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL385,6823.45CEUX--BATE--AQEU--TQEX--Total385,6823.45 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra
Trading in Novo Nordisk shares by board members, executives and associated persons6.5.2024 21:02:16 CEST | Press release
Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Novo Holdings A/S, associated to Kasim Kutay 2 Reason for the notification a) Position/status Member of the Board of Directors b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A&S b) LEI 549300DAQ1CVT6CXN342